Buy ATP adenosine triphosphate Na solution for injection 1% 1ml No. 10 in pharmacies

Pharmacodynamics and pharmacokinetics

ATP-Long is a drug in a new category of substances that has a molecule containing ATP , and magnesium salts , as well as histidine amino acids . The drug exhibits a specific, unique pharmacological effect that is not typical for its other chemical ingredients.

It has a stimulating effect on energy metabolism , helps normalize the level of saturation with magnesium and potassium , activates ion transport systems of cell membranes, reduces uric acid , and develops the protective antioxidant function of the myocardium.

In patients with paroxysmal supraventricular and supraventricular tachycardia , flutter and atrial fibrillation, the use of the drug helps restore natural sinus rhythm , as well as reduce the intensity of ectopic foci (ventricular and atrial extrasystoles ).

During hypoxia and ischemia, ATP-Long has antiarrhythmic, membrane-stabilizing and anti-ischemic activity, due to its ability to establish metabolic processes in the myocardium . It has a beneficial effect on coronary circulation , peripheral and central hemodynamics , increases the contractility of the heart muscle, improves cardiac output and left ventricular functionality.

This range of effects has a positive effect on physical performance, and also leads to a decrease in the number of attacks of shortness of breath and angina pectoris during physical work, which is what ATP-Long is used for.

Pharmacological properties of the drug Atf-long

The cardiological drug ATP-Long is an original drug of a new class of substances - multi-ligand coordination compounds with high-energy phosphates, the molecule of which consists of adenosine-5'-triphosphate (ATP), the amino acid histidine and magnesium and potassium salts. Due to the original structure of the molecule, the drug has a characteristic pharmacological effect that is absent in any of its other chemical components (ATP, histidine, K+, Mg++). ATP-Long stimulates energy metabolism, the activity of ion transport systems of cell membranes, normalizes the concentration of potassium and magnesium ions, indicators of the lipid composition of membranes, the activity of membrane-dependent enzymes, improves the antioxidant system of myocardial protection, and reduces the concentration of uric acid. ATP-Long has anti-ischemic, membrane-stabilizing, anti-arrhythmic effects due to the normalization of metabolic processes in the myocardium during ischemia and hypoxia. ATP-Long improves central and peripheral hemodynamics, coronary circulation, increases myocardial contractility, functional state of the left ventricle and cardiac output, which leads to improved physical performance. Under conditions of ischemia, the drug reduces myocardial oxygen consumption, improves coronary circulation, and activates the functional state of the heart, which leads to a reduction in the frequency of angina attacks and shortness of breath during exercise. The drug restores normal sinus rhythm in patients with paroxysmal supraventricular and supraventricular tachycardia with atrial fibrillation and flutter, and also reduces the activity of ectopic foci (atrial and ventricular extrasystoles). ATP-Long normalizes the concentration of potassium and magnesium in tissues.

Indications for use

The drug ATP-Long is indicated for use in complex treatment for:

• unstable angina;
• coronary heart disease;
• angina pectoris of exertion and rest;
• heart failure;
• myocardial and post-infarction cardiosclerosis ;
• supraventricular tachycardia ;
• heart rhythm disturbances;
• supraventricular paroxysmal tachycardia;
• vegetative-vascular dystonia;
• myocarditis of infectious-allergic nature;
• myocardial dystrophy;
• hyperuricemia of various origins;
• chronic fatigue syndrome ;
• surgical interventions in the pre- and postoperative periods;
• coronary syndromes , especially with nitrate intolerance, in order to enhance antiarrhythmic effectiveness and reduce the side effects of antiarrhythmic drugs.

ATF-long tablets 20 mg No. 40

• heart rhythm disturbances;

• vegetative-vascular dystonia;

• myocardial dystrophy;

• myocarditis;

• chronic fatigue syndrome.

Used to increase tolerance to physical activity.

Contraindications.

• Hypersensitivity to the components of the drug;

• acute myocardial infarction;

• cardiogenic and other types of shock;

• obstructive diseases of the bronchopulmonary system;

• severe forms of bronchial asthma;

• sinoatrial blockade II-III degree;

• atrioventricular (AV) blockade of II-III degree;

• hyperkalemia, hypermagnesemia;

• hemorrhagic stroke.

Interaction with other drugs and other types of interactions.

Cardiac glycosides: increased risk of atrioventricular block. Potassium-sparing diuretics, potassium supplements and ACE inhibitors: the risk of hyperkalemia increases.

Magnerot and other magnesium preparations: hypermagnesemia may develop.

Dipyridamole enhances the therapeutic effect of ATP-LONG®.

Xanthinol nicotinate, caffeine, theophylline, aminophylline: reduce the therapeutic effect of the drug ATP-LONG®.

ATP-LONG® can enhance the antianginal effect of alpha and beta adrenergic blockers, calcium channel blockers, and nitrates.

Features of application.

Use with caution:

• with severe arterial hypotension;

• with cardiac glycosides due to an increased risk of atrioventricular block.

With long-term use, it is necessary to monitor the level of potassium and magnesium in the blood. Prescribe with caution if you are prone to bronchospasms.

The drug contains sucrose and lactose, so patients with diabetes should use the drug with caution; patients with hereditary intolerance to fructose, glucose-galactose, sucrose-isomaltose should not use the drug.

Limit consumption of products containing caffeine (coffee, tea, cola drinks).

Use during pregnancy or breastfeeding.

Use by pregnant women is contraindicated.

Breastfeeding should be stopped during treatment.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

If dizziness and a decrease in blood pressure are observed during treatment with the drug, you should refrain from driving vehicles and other mechanisms.

Method of administration and dose.

Take ATP-LONG® tablets under the tongue and keep until completely absorbed. Single dose - 10-40 mg 3-4 times a day, regardless of meals. The duration of treatment is determined by the doctor, on average it is 20–30 days. If necessary, repeat the course after 10–15 days. The maximum daily dose is 160 mg.

Children.

Do not use in children.

Overdose.

The development of bradycardia, AV block, arterial hypotension, and syncope is possible.

Treatment. Stop taking the drug and begin symptomatic therapy. For bradycardia, administer atropine sulfate.

Adverse reactions.

Immune system, skin and subcutaneous tissue: allergic reactions, incl. skin rashes, itching, Quincke's edema, facial hyperemia.

Respiratory system: bronchospasm.

Cardiovascular system: decreased blood pressure, tachycardia, AV block.

Nervous system: headache, dizziness.

Digestive tract: nausea, feeling of discomfort in the epigastric region, increased motility of the digestive tract.

Urinary system: increased diuresis.

Vessels: feeling of heat.

With prolonged and uncontrolled use - hyperkalemia or hypermagnesemia.

Best before date.

2 years.

Storage conditions.

In original packaging at temperatures from 2 °C to 8 °C.

Keep out of the reach of children.

Package.

10 tablets per blister, 4 blisters per pack.

Vacation category.

Over the counter.

Manufacturer.

Public Joint Stock Company “Research and Production.

Contraindications

• cardiogenic , as well as other types of shock ;
• hyperkalemia;
• lactation;
• hypersensitivity to ingredients;
• myocardial infarction in the acute period;
• pregnancy;
• hypermagnesemia;
• childhood;
• obstructive pathologies of the bronchi and lungs;
• AV block and sinoatrial block (2-3 degree);
• severe bronchial asthma
• hemorrhagic stroke.

Side effects

• feeling of discomfort in the chest and epigastric region;
• itchy skin;
• nausea;
• rashes on the skin;
• decreased blood pressure;
• bronchospasm;
• hyperemia ;
• tachycardia;
• headache;
• increased diuresis;
• feeling of heat;
• dizziness;
• increased gastrointestinal motility;
• Quincke's edema;
• hypermagnesemia or hyperkalemia (in case of uncontrolled and prolonged use).

Instructions for use of ATF-Long

ATP-Long tablets, instructions for use

ATP-Long tablets are recommended to be taken sublingually (under the tongue) until completely absorbed. Reception is carried out regardless of food 3-4 times in 24 hours, in a single dose of 10-40 mg. The average period of taking the tablets is 20-30 days (further use is on the recommendation of a doctor). It is possible to repeat the course of treatment after 10-15 days. It is not recommended to exceed the maximum daily dose of 160 mg.

ATP-Long injection solution, instructions for use

ATP-Long injection solution is administered 1-2 times every 24 hours, intramuscularly, 1-2 ml, at a rate of 0.2-0.5 mg/kg.

Intravenous administration is carried out in the form of infusions (slowly) in a dose of 1-5 ml, at a rate of 0.05-0.1 mg/kg/min. Infusions are carried out in a hospital setting and under blood pressure control. The average duration of therapy is 10-14 days.

Mode of application

ATP-long is prescribed 3-4 times a day, 10-40 mg. The average duration of therapy is 20-30 days. The course of treatment can be repeated after 10-15 days. In the treatment of arrhythmias and acute cardiac conditions, ATP-long is prescribed as follows: a single dose of 10 to 40 mg is taken 10 minutes later until acute symptoms are relieved. The maximum daily dosage of the drug is 400-600 mg. ATP-long tablets are taken sublingually and completely dissolve. Taking the drug does not depend on food.

Interaction

Parallel use of cardiac glycosides increases the possibility of AV blockade .

Co-administration of magnesium can lead to hypermagnesemia .

Combination with Dipyridamole enhances the effect of ATP-Long, and with Aminophylline , Caffeine , Xanthinol Nicotinate , Theophylline , on the contrary, reduces its effectiveness.

ACE inhibitors , potassium and potassium-sparing diuretics increase the risk of hyperkalemia .

ATP-Long can enhance the antianginal effectiveness of calcium channel blockers , beta-blockers and nitrates .

pharmachologic effect

Anti-ischemic, membrane stabilizing. ATP-long is a multi-ligand coordination compound with high-energy phosphates, containing in the ATP molecule, magnesium and potassium salts, and the amino acid histidine. The drug has the ability to stimulate energy metabolism, activate ion transport systems of cell membranes, restore the necessary concentrations of magnesium and potassium ions, and improve the antioxidant system that provides myocardial protection. ATP-long activates membrane-dependent enzymes, restores the lipid composition of cell membranes and reduces the content of uric acid. Due to the ability to correct metabolic processes in the myocardium under conditions of hypoxia and ischemia, ATP-long has a membrane-stabilizing, antiarrhythmic and anti-ischemic effect. ATP-long is characterized by the ability to improve hemodynamics of both central and peripheral blood flow, increase cardiac output, contractility of the heart muscle and functional activity of the left ventricle, thereby increasing physical performance. The drug is able to reduce oxygen consumption by the heart muscle under conditions of ischemia, improve blood circulation in the coronary vessels, activate the functional state of the heart muscle, resulting in a reduction in the frequency of angina attacks and shortness of breath during exercise. ATP-long in patients with paroxysmal supraventricular tachycardia or supraventricular tachycardia, as well as atrial flutter and fibrillation, is able to restore sinus rhythm and reduce the activity of ectopic foci (ventricular and atrial extrasystoles).

special instructions

Both tablets and injections of the drug should be used with caution in conjunction with cardiac glycosides and in case of arterial hypotension and, due to the risk of AV blockade , as well as in diabetes mellitus , the patient’s predisposition to bronchospasm , fructose, sucrose-isomaltose, glucose tolerance disorders -galactose (for tablets).

Long-term use should be combined with monitoring plasma levels of magnesium and potassium .

During therapy, the consumption of caffeine-containing products should be limited.

Analogs

Level 4 ATX code matches:
Vazonat

Phosphaden

Hawthorn fruit

Preductal

Meldonium

Angiosil Retard

Ranexa

Lily of the valley tincture

Neocardil

Rimecore

Triductane

Hawthorn tincture

Triductan MV

Trimectal MV

Trimectal

Neoton

Predisin

Trimetazidine

Tivortin Aspartate

Metamax

• Adexor;
• Vasopro;
• Dibikor;
• Vazonat;
• Cardazin;
• Kapikor;
• Coraxan;
• Cardimax;
• Mexicor;
• Metamax;
• Mildronate;
• Methonate;
• Neocardil;
• Preductal;
• Riboxin;
• Thiotriazolin;
• Triductane;
• Trimetazidine;
• Energoton , etc.

Reviews for ATF-Long

As a rule, reviews of ATP-Long are neutral and most likely this is due to the frequent use of this drug in combination with other drugs, the effects of which often overlap to such an extent that it becomes difficult to determine which drug has a positive effect on the body.

The same situation occurs with side effects and undesirable consequences.

If you have been prescribed this medication, you should rely on the doctor’s opinion and strictly follow his recommendations and instructions.

Buy ATP adenosine triphosphate Na solution for injection 1% 1ml No. 10 in pharmacies

Adenosine triphosphoric acid Buy Adenosine triphosphoric acid in pharmacies MANUFACTURERS North China Pharmaceutical Group (China) GROUP Metabolism stimulants - derivatives of adenosine and hypoxanthine

COMPOSITION Trifosadenine.

INTERNATIONAL NON-PROPENTED NAME Trifosadenine

Pharmachologic effect:

Sodium adenosine triphosphate is a drug that regulates energy metabolism. In the body, sodium adenosine triphosphate is hydrolyzed to form ATP (adenosine triphosphoric acid), which in turn breaks down into ADP (adenosine diphosphoric acid) and inorganic phosphate when interacting with actomyosin. During the breakdown of ATP, energy is released, which is used by the body to ensure the process of synthesis of various substances, as well as the implementation of mechanical functions.

When using the drug, there is a decrease in smooth muscle tone, normalization of the conduction of nerve impulses in the autonomic nodes, as well as transmission of excitation from the vagus nerve to the heart. Due to ATP metabolism, there is some suppression of Purkinje fibers and the sinus node.

Indications for use:

The drug is used in combination with other drugs to treat patients suffering from muscular dystrophy and atrophy, as well as patients with diseases accompanied by peripheral vascular spasm (including intermittent claudication, Raynaud's disease and thromboangiitis obliterans).

The drug is prescribed to relieve paroxysms of supraventricular tachycardia.

The drug can be prescribed as a means of stimulating labor.

ATP-Forte is used to treat patients suffering from peripheral, central or mixed forms of hereditary retinal pigmentary degeneration.

Method of application:

The drug is intended for parenteral use. Usually the drug is administered intramuscularly; in severe cases, including for the relief of supraventricular tachyarrhythmia, the drug is administered intravenously. The duration of the course of treatment and the dose of the drug are determined by the attending physician individually for each patient.

Adults with muscular dystrophy or peripheral circulatory disorders are usually prescribed 1 ml of the drug 1 time per day intramuscularly for 2 days, after which they switch to 1 ml of the drug 2 times a day intramuscularly. It is also possible to prescribe the drug in a dose of 2 ml once a day from the first day of therapy; in this case, the dose is not changed during the course of treatment.

The duration of treatment is usually 30-40 days. If necessary, 30-60 days after the end of the course of treatment, a repeat course is prescribed.

Adults with hereditary retinal pigmentary degeneration are usually prescribed 5 ml of the drug 2 times a day intramuscularly. The interval between injections should be 6-8 hours.

The duration of treatment is usually 15 days. If necessary, the course of treatment is repeated every 8-12 months.

For the purpose of stopping supraventricular tachyarrhythmia, adults are usually prescribed 1-2 ml of the drug intravenously. The drug should be administered within 5-10 seconds. If the therapeutic effect of the drug is not sufficiently pronounced, re-administration of the drug is prescribed after 2-3 minutes.

Adverse events:

The drug is usually well tolerated by patients.

In some cases, with intramuscular administration of the drug, headache, tachycardia and increased diuresis may develop.

When administered intravenously, some patients experienced nausea, vomiting, headache, and redness of the face and upper body.

It is also possible to develop allergic reactions.

The development of severe side effects requires discontinuation of the drug.

Contraindications:

Increased individual sensitivity to the components of the drug.

The drug is not prescribed to patients with acute myocardial infarction.

The drug is not used to treat children under 18 years of age due to the lack of reliable data on the safety and effectiveness of the drug in this age category.

During pregnancy:

There are no data on the safety of the drug during pregnancy and lactation. During pregnancy, the drug can be prescribed by the attending physician if the expected benefit to the mother is higher than the potential risks to the fetus.

Interaction with other drugs:

The combined use of the drug with high doses of cardiac glycosides is contraindicated.

Overdose:

At the moment, there have been no reports of drug overdose.

Release form of the drug:

Solution for parenteral use, 1 ml in ampoules, 10 ampoules in a cardboard package.

Storage conditions:

It is recommended to store the drug in a dry place away from direct sunlight at a temperature of 3 to 5 °C.

Shelf life : 1.5 years.

Compound:

1 ml of the drug (1 ampoule) contains:

Sodium adenosine triphosphate disubstituted (in terms of adenosine triphosphate acid) - 10 mg,

Excipients.

Drugs with similar effects:

Etadenum Rikavitum Atriphos Potassium orotate Kaliiorotas Nucleo CMP forte

ATF-Long price, where to buy

The average price of ATF-Long is:

• tablets 10 mg No. 40 – 60 hryvnia;
• tablets 20 mg No. 40 – 90 hryvnia;
• ampoules 1 ml No. 10 – 25 hryvnia.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine

LuxPharma* special offer

• ATP-long tablets 20 mg 40 pcs.
  1850 rub. order

show more

Pharmacy24

• ATF-Long 0.01g No. 40 tablets PAT NEC "Borshchagivsky chemical and pharmaceutical plant", Kiev, Ukraine
  58 UAH. order
• ATF-Long 20 mg No. 40 tablets TOV FC Farkos, Ukraine

  72 UAH order

• ATF-Long 0.02g No. 40 tablets PAT NEC "Borshchagivsky chemical-pharmaceutical plant", Kiev, Ukraine

  85 UAH order